Lakeway, NY -- (SBWIRE) -- 03/04/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Cell Therapeutics Inc (NASDAQ:CTIC) shares declined 7.06% to $1.25 in the previous trading session. The company, on Jan. 31, announced that the Gynecologic Oncology Group (GOG) informed CTIC that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIOTM (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis.
CTIC remains blinded to the interim analysis results. GOG-0212 is the largest maintenance study in this setting, having enrolled approximately 1,000 of the planned 1,100 patients. Enrollment is expected to be completed in 2013.
Is CTIC a Still a Buy after the Solid momentum? Let’s Find out Here
Cincinnati Bell Inc. (NYSE:CBB) shares decreased 7.38% to $3.01. The company, on Feb. 27, said that fourth quarter revenue increased 3% to $375 million. Due to special items, net income resulted in a $9.8 million loss, or a loss of 6 cents per share. Net income increased 20.6% for the quarter. Analysts expected earnings of $0.05 on revenue of 367.72 million.
Additionally, the company announced its participation in the Raymond James 34th Annual Institutional Investors Conference on Monday, March 4, 2013 at 2:15 p.m. Eastern Time. Ted Torbeck, president and chief executive officer of Cincinnati Bell Inc., will be presenting at the conference.
Is CBB a Strong Buying Opportunity After The Recent Slump? Find out Here
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) shares dropped 7.32% and closed at $3.36 in the last trading session. The company, on Feb. 25, announced that it has closed its previously announced underwritten public offering of 8.0 million common shares, at a public offering price of $4.00 per common share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Oncolytics, were approximately $32.0 million.
Should ONCY Buy ONCY After The Recent Movement? Let’s Find out Here
EV Energy Partners, L.P. (NASDAQ:EVEP) shares declined 7.16% to $52 after the company, on Mar. 1, reported fourth-quarter net loss of $9.68 million or $0.23 per share, as compared to net income of $9.47 million or $0.27 per share in the prior year quarter. Total revenues for the quarter rose to $75.50 million from $66.84 million in the year ago quarter. Analysts expected the company to report earnings of $0.43 per share on revenues of $83.93 million for the quarter.
Is EVEP a Strong Buying Opportunity After The Recent Slump? Find out Here
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)